Ovine trophoblast protein-one inhibits development of endometrial responsiveness to oxytocin in ewes.
In experiment (Exp) 1, 12 cyclic ewes had catheters placed into each uterine horn on Day 7 (estrus = Day 0). On Days 11-15, 6 ewes received twice-daily intrauterine infusions of 1.5 mg serum protein (SP) into each uterine horn and 6 ewes received infusions of 1.08 mg SP + 0.42 mg ovine conceptus secretory proteins (oCSP) containing 25 micrograms ovine trophoblast protein-one (oTP-1) as determined by radioimmunoassay (25-35% bioactive by antiviral assay). SP-infused and oCSP-infused ewes had similar plasma 13,14-dihydro-15-keto prostaglandin F2 alpha (PGF2 alpha) profiles in response to oxytocin on Day 11, but SP ewes became more responsive (p less than 0.01) to oxytocin on Days 13 and 15 than oCSP ewes. SP ewes also had greater incorporation of [3H]inositol into inositol trisphosphate (IP3) (+3449%, p less than 0.01) and total inositol phosphate (IP) (+760%, p less than 0.08), in response to oxytocin, than did oCSP ewes (+553 and +168% for IP3 and total IP, respectively) in endometrium collected at ovariectomy/hysterectomy on Day 16. Mean CL weights on Day 16 and mean concentrations of progesterone in plasma collected at 12-h intervals on Days 6-16 were not different for SP and oCSP ewes, but concentrations of progesterone were lower (p less than 0.05) in SP ewes on Days 15-16 than for oCSP ewes. These results indicate that oTP-1 may prevent luteolysis by inhibiting development of endometrial responsiveness to oxytocin and, therefore, reduce oxytocin-induced synthesis of IP3 and PGF2 alpha.(ABSTRACT TRUNCATED AT 250 WORDS)
Mirando
M A
MA
Animal Science Department, University of Florida, Gainesville 32611.
Ott
T L
TL
Harney
J P
JP
Bazer
F W
FW
D000818:Animals; D015237:Dinoprost / Q000378:metabolism; D004717:Endometrium / Q000187:drug effects* / Q000502:physiology; D005260:Female; D007295:Inositol Phosphates / Q000378:metabolism; D007370:Interferon Type I; D008183:Luteal Phase / Q000187:drug effects / Q000502:physiology; D008186:Luteolytic Agents / Q000037:antagonists & inhibitors; D010121:Oxytocin / Q000494:pharmacology*; D011257:Pregnancy Proteins / Q000494:pharmacology*; D011945:Receptors, Angiotensin / Q000187:drug effects / Q000378:metabolism; D018045:Receptors, Oxytocin; D012756:Sheep
D007295:Inositol Phosphates; D007370:Interferon Type I; D008186:Luteolytic Agents; D011257:Pregnancy Proteins; D011945:Receptors, Angiotensin; D018045:Receptors, Oxytocin; C020947:interferon tau; D010121:Oxytocin; D015237:Dinoprost